pexidartinib + pembrolizumab

Plexxikon MOA pexidartinib-pembrolizumab

Targeted Indication Status Sites link to clinicaltrials.gov

Solid Tumors:
Melanoma, NSCLC, Ovarian,
TNBC, SCCHN, Bladder, 
PDAC, Gastric, GIST, 
Cholangiocarcinoma, 
Leiomyosarcoma

Phase 1/2a

Los Angeles, CA
Detroit, MI
Scottsdale, AZ
San Antonio, TX
New York, NY
Boston, MA
Nashville, TN
Baltimore, MD
St. Louis, MO
Charleston, SC
San Francisco, CA
Greenbrae, CA

NCT02452424

These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation. Image above depicts proposed targeted pathway of the investigational agent(s) in the targeted indication.

Zhu Y et al. Cancer Research. 2014; 74(18); 5057-69. Quail DF, Joyce JA. Nat Med. 2013; 19(11); 1423-37.
Mok S et al. Cancer Research. 2013; 74(1); 153-61. Qualls JE, Murray PJ. Nature Med. 2010; 16(8); 863-4.